BioBusiness

Articles

GlaxoSmithKline and iTeos Therapeutics enter into a development and commercialization collaboration worth up to $2.08 billion for a new therapeutic anti-cancer mAb candidate.

GSK and iTeos Therapeutics Enter mAb Collaboration

FDA has granted fast track designation to a GLP-1/glucagon dual agonist in development by Boehringer Ingelheim and Zealand Pharma for the treatment of NASH.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for NASH Treatment

FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.

Janssen Receives FDA Breakthrough Therapy Designation for Multiple Myeloma mAb

FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.

FDA Grants Accelerated Approval for Biogen’s Alzheimer’s Drug

Feliza Mirasol is the science editor for 

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Next-Gen Therapies Drive Development Technologies

Both the European Commission and FDA have granted approval to GlaxoSmithKline’s Jemperli (dostarlimab) for treating endometrial cancer.

GSK Gets EC and FDA Approval for Endometrial Cancer Biologic, Jemperli

This new collaboration between Vyant Bio, Ordaōs Bio, and Cellaria mitigates risk in the drug discovery process using artificial intelligence and in-vitro “avatar” clinical trials.

Vyant Bio, Ordaōs Bio, and Cellaria, Collaborate on Biomarker-Specific Small Protein Therapeutics

A growing pipeline of gene therapy candidates aimed at treating neurodegenerative diseases has prompted new guidance.

Gene Therapies Target Neurodegenerative Diseases

Editor of Pharmaceutical Technology Europe

Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.

Balancing Innovation Protection and Affordability

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Biologic Drugs in Development